NEXTPro
Description
NEXTPro develops a 177Lu-based radioligand therapy targeting prostatic acid phosphatase (PAP) for prostate cancer patients not responding to PSMA therapies.
The project validates the lead candidate NEXTPro-131 through
- translational biodistribution,
- dosimetry,
- efficacy, and
- safety studies.
Key data
Projectlead
Project team
Project status
ongoing, started 06/2026
Institute/Centre
Institute of Chemistry and Biotechnology (ICBT)
Funding partner
Innosuisse Innovationsprojekt
School of Life Sciences and Facility Management
Einsiedlerstrasse 31
8820 Wädenswil